Clinical Takeaway
In this randomized controlled crossover trial, autistic children aged 5 to 12 received weight-based oral CBD oil at 10 mg/kg/day for 12 weeks, with outcomes measured across social relating, anxiety, and parental stress. The study used a double-blind, placebo-controlled design with 29 participants, providing a higher level of evidence than most prior observational or open-label cannabis research in this population. Results from this trial offer clinically meaningful data on whether terpene-containing CBD oil produces measurable benefits beyond placebo in pediatric autism.
#28 Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomized Controlled Crossover Trial.
Citation: Parrella Nina-Francesca et al.. Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomized Controlled Crossover Trial.. Autism research : official journal of the International Society for Autism Research. 2026. PMID: 41452412.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 3 Human: 1 Risk: -2
- Preclinical only
Abstract: Cannabidiol (CBD), a non-intoxicating compound derived from the cannabis plant, has garnered increasing attention as a potential pharmacological therapeutic for autism. We conducted a randomized, double-blind, placebo-controlled, crossover trial to understand whether oral CBD oil containing terpenes can improve outcomes in autistic children. Twenty-nine children (18 male), aged 5 to 12โyears (Mโ=โ9.62โyears, SDโ=โ2.05), diagnosed with autism spectrum disorder, completed the study. Participants received weight-based dosing of CBD oil (10โmg/kg/day) or matched placebo oil over two 12-week intervention periods (crossover), separated by an 8-week washout period. Outcome measures included the Social Responsiveness Scale-2 (SRS-2; primary outcome), PROMIS Social Relating, Anxiety, and Sleep, Developmental Behavior Checklist-2 (DBC-2), Vineland-3, and Autism Parenting Stress Index (APSI; secondary outcomes). There was no significant effect observed for the primary outcome measure (SRS-2) for CBD oil relative to placebo oil after 12โweeks (ฮฒโ=โ-11.15, SEโ=โ7.19, pโ=โ0.125). Significant improvements were observed in secondary measures of social functioning, including DBC-2 Social Relating (ฮฒโ=โ-2.35, SEโ=โ0.92, p(adj)โ=โ0.024), as well as reduced anxiety on the DBC-2 subscale (ฮฒโ=โ-3.20, SEโ=โ0.94, p(adj)โ=โ0.002), and lower parental stress (APSI; ฮฒโ=โ-4.63, SEโ=โ2.26, p(adj)โ=โ0.044). No differences were detected on Vineland-3 adaptive functioning (ABC: ฮฒโ=โ2.06, SEโ=โ2.67, p(adj)โ=โ1.000), and domain scores were not significant. Safety and tolerability data indicated that two children experienced gastrointestinal discomfort while taking CBD. Findings from this pilot trial suggest that while CBD combined with terpenes did not improve the primary outcome of social responsiveness, it may hold potential in addressing certain autism-related difficulties, particularly anxiety and social relating. Further research with larger sample sizes is needed to fully evaluate the efficacy
|
